Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#3056 Multi-Omic Characterization and Evolution of Neuroendocrine Neoplasm Organoids
Introduction: Molecular characterizations of neuroendocrine neoplasm (NENs) have unveiled candidate alterations associated with aggressiveness and suggested that the molecular link between neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) might be subtler than initially thought. For example, we have recently unveiled a new entity of pulmonary carcinoids (supra-carcinoids) with carcinoid-like morphology yet the molecular and clinical features of large cell neuroendocrine carcinoma (LCNEC). Testing hypotheses to explain aggressiveness and the possibility of progression or transition from NET to NEC through the accumulation of genetic anomalies requires in vitro and in vivo experimental models.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Foll M
Authors: Alcala N, Dayton T, Mangiante L, Delhomme T, Tabone-Egling S,
Keywords: organoids, omics, evolution, lung, pancreas, bioinformatics,
Introduction: The identification of a sensitive biomarker to detect the presence and severity of carcinoid heart disease could allow more selective use of clinical and echocardiographic screening. ST2 is a protein belonging to the family of interleukin 1 receptors, present both in the isoform of transmembrane (ST2L) and in the soluble one (sST2). sST2 blocks the anti-inflammatory, anti-hypertrophic, and anti-fibrotic effects of cytokine IL-33 on the myocardium and recent studies have shown that sST2 levels increase in the blood of patients diagnosed with heart failure.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Salvatici M, Zorzino L, Fabiani I, Cardinale D, Fazio N,
Keywords: sST2, Biomarkers, Carcinoid Heart Disease,
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Bodei L
Authors: Bodei L, Kidd M, Singh A, van der Zwan W, Severi S,
Keywords: biomarker, PRRT, prediction, NETest, PPQ, CgA, personalized medicine,
Introduction: Health related quality of life (HRQoL) is increasingly important as a concept reflecting the patients’ perspective in conjunction with the disease presentation severity and treatment. Understanding the impact of treatment on neuroendocrine tumour (NET) patients’ HRQoL is paramount given the nature of the disease.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Fountain D, Leeuwenkamp O, Watson C, Longworth L,
Keywords: Gastro-entero-pancreatic neuroendocrine tumours, Quality of Life, 177Lu-Dotatate, EORTC QLQ-C30,
#2216 Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker
Introduction: We have developed a blood-based tool (gene expression analysis and tumor grade) for predicting PRRT efficacy.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Bodei L
Authors: Bodei L, Kidd M, van der Zwan W, Singh A, Severi S,
Keywords: Biomarker, carcinoid, PRRT, prediction, therapy, efficacy, stratification,